APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Cardiovascular Disease Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Cardiovascular Disease Drugs Market Outlook and Growth Opportunities 2026

Report ID 173975160427 December 2025191 pages

Choose your research edition.

Industry ResearchCardiovascular Disease Drugs Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Cardiovascular Disease Drugs Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Cardiovascular Disease Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cardiovascular Disease Drugs Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Cardiovascular Disease Drugs Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Cardiovascular Disease Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Cardiovascular Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cardiovascular Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cardiovascular Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Cardiovascular Disease Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Cardiovascular Disease Drugs market include Takeda Pharmaceutical, Sanofi, Johnson＆Johnson, Novartis, Merck, Roche, Pfizer, Bayer and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Cardiovascular Disease Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cardiovascular Disease Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cardiovascular Disease Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cardiovascular Disease Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Cardiovascular Disease Drugs Segment by Company

Takeda Pharmaceutical

Sanofi

Johnson＆Johnson

Novartis

Merck

Roche

Pfizer

Bayer

AstraZeneca

United Therapeutics Corporation

Daiichi Sankyo Company Limited

Boehringer Ingelheim

Astellas Pharma

Actelion Pharmaceuticals

Cardiovascular Disease Drugs Segment by Type

Lotrel

Zebeta

Coumadin

Sectral

Heparin

Lopressor

Norvasc

Toprol XL

Others

Cardiovascular Disease Drugs Segment by Application

Stroke

Dyslipidemia

Thrombosis

Peripheral Artery Disease

Asischemic Heart Disease

Coronary Artery Diseases

Atherosclerosis

Others

Cardiovascular Disease Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Cardiovascular Disease Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Cardiovascular Disease Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Cardiovascular Disease Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Cardiovascular Disease Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cardiovascular Disease Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cardiovascular Disease Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cardiovascular Disease Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Cardiovascular Disease Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cardiovascular Disease Drugs industry.

Chapter 3: Detailed analysis of Cardiovascular Disease Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Cardiovascular Disease Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Cardiovascular Disease Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Cardiovascular Disease Drugs Industry Trends Table 2. Cardiovascular Disease Drugs Industry Drivers Table 3. Cardiovascular Disease Drugs Industry Opportunities and Challenges Table 4. Cardiovascular Disease Drugs Industry Restraints Table 5. Global Cardiovascular Disease Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Cardiovascular Disease Drugs Revenue Share by Company (2021-2026) Table 7. Global Cardiovascular Disease Drugs Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Cardiovascular Disease Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Cardiovascular Disease Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Cardiovascular Disease Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Cardiovascular Disease Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Cardiovascular Disease Drugs Company, Product Type & Application Table 13. Global Cardiovascular Disease Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Cardiovascular Disease Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Lotrel Table 18. Significant Companies of Zebeta Table 19. Significant Companies of Coumadin Table 20. Significant Companies of Sectral Table 21. Significant Companies of Heparin Table 22. Significant Companies of Lopressor Table 23. Significant Companies of Norvasc Table 24. Significant Companies of Toprol XL Table 25. Significant Companies of Others Table 26. Global Cardiovascular Disease Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 27. Global Cardiovascular Disease Drugs Sales Volume by Type (2021-2026) & (W Units) Table 28. Global Cardiovascular Disease Drugs Sales Volume by Type (2027-2032) & (W Units) Table 29. Global Cardiovascular Disease Drugs Sales Volume Share by Type (2021-2026) Table 30. Global Cardiovascular Disease Drugs Sales Volume Share by Type (2027-2032) Table 31. Global Cardiovascular Disease Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Cardiovascular Disease Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 33. Global Cardiovascular Disease Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 34. Global Cardiovascular Disease Drugs Sales Value Share by Type (2021-2026) Table 35. Global Cardiovascular Disease Drugs Sales Value Share by Type (2027-2032) Table 36. Significant Companies of Stroke Table 37. Significant Companies of Dyslipidemia Table 38. Significant Companies of Thrombosis Table 39. Significant Companies of Peripheral Artery Disease Table 40. Significant Companies of Asischemic Heart Disease Table 41. Significant Companies of Coronary Artery Diseases Table 42. Significant Companies of Atherosclerosis Table 43. Significant Companies of Others Table 44. Global Cardiovascular Disease Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 45. Global Cardiovascular Disease Drugs Sales Volume by Application (2021-2026) & (W Units) Table 46. Global Cardiovascular Disease Drugs Sales Volume by Application (2027-2032) & (W Units) Table 47. Global Cardiovascular Disease Drugs Sales Volume Share by Application (2021-2026) Table 48. Global Cardiovascular Disease Drugs Sales Volume Share by Application (2027-2032) Table 49. Global Cardiovascular Disease Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Cardiovascular Disease Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 51. Global Cardiovascular Disease Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 52. Global Cardiovascular Disease Drugs Sales Value Share by Application (2021-2026) Table 53. Global Cardiovascular Disease Drugs Sales Value Share by Application (2027-2032) Table 54. Global Cardiovascular Disease Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 55. Global Cardiovascular Disease Drugs Sales by Region (2021-2026) & (W Units) Table 56. Global Cardiovascular Disease Drugs Sales Market Share by Region (2021-2026) Table 57. Global Cardiovascular Disease Drugs Sales by Region (2027-2032) & (W Units) Table 58. Global Cardiovascular Disease Drugs Sales Market Share by Region (2027-2032) Table 59. Global Cardiovascular Disease Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Cardiovascular Disease Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 61. Global Cardiovascular Disease Drugs Sales Value Share by Region (2021-2026) Table 62. Global Cardiovascular Disease Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 63. Global Cardiovascular Disease Drugs Sales Value Share by Region (2027-2032) Table 64. Global Cardiovascular Disease Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 65. Global Cardiovascular Disease Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 66. Global Cardiovascular Disease Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 67. Global Cardiovascular Disease Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 68. Global Cardiovascular Disease Drugs Sales by Country (2021-2026) & (W Units) Table 69. Global Cardiovascular Disease Drugs Sales Market Share by Country (2021-2026) Table 70. Global Cardiovascular Disease Drugs Sales by Country (2027-2032) & (W Units) Table 71. Global Cardiovascular Disease Drugs Sales Market Share by Country (2027-2032) Table 72. Global Cardiovascular Disease Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 73. Global Cardiovascular Disease Drugs Sales Value Market Share by Country (2021-2026) Table 74. Global Cardiovascular Disease Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 75. Global Cardiovascular Disease Drugs Sales Value Market Share by Country (2027-2032) Table 76. Takeda Pharmaceutical Company Information Table 77. Takeda Pharmaceutical Business Overview Table 78. Takeda Pharmaceutical Cardiovascular Disease Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Takeda Pharmaceutical Cardiovascular Disease Drugs Product Portfolio Table 80. Takeda Pharmaceutical Recent Development Table 81. Sanofi Company Information Table 82. Sanofi Business Overview Table 83. Sanofi Cardiovascular Disease Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Sanofi Cardiovascular Disease Drugs Product Portfolio Table 85. Sanofi Recent Development Table 86. Johnson＆Johnson Company Information Table 87. Johnson＆Johnson Business Overview Table 88. Johnson＆Johnson Cardiovascular Disease Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Johnson＆Johnson Cardiovascular Disease Drugs Product Portfolio Table 90. Johnson＆Johnson Recent Development Table 91. Novartis Company Information Table 92. Novartis Business Overview Table 93. Novartis Cardiovascular Disease Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Novartis Cardiovascular Disease Drugs Product Portfolio Table 95. Novartis Recent Development Table 96. Merck Company Information Table 97. Merck Business Overview Table 98. Merck Cardiovascular Disease Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Merck Cardiovascular Disease Drugs Product Portfolio Table 100. Merck Recent Development Table 101. Roche Company Information Table 102. Roche Business Overview Table 103. Roche Cardiovascular Disease Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Roche Cardiovascular Disease Drugs Product Portfolio Table 105. Roche Recent Development Table 106. Pfizer Company Information Table 107. Pfizer Business Overview Table 108. Pfizer Cardiovascular Disease Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Pfizer Cardiovascular Disease Drugs Product Portfolio Table 110. Pfizer Recent Development Table 111. Bayer Company Information Table 112. Bayer Business Overview Table 113. Bayer Cardiovascular Disease Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Bayer Cardiovascular Disease Drugs Product Portfolio Table 115. Bayer Recent Development Table 116. AstraZeneca Company Information Table 117. AstraZeneca Business Overview Table 118. AstraZeneca Cardiovascular Disease Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. AstraZeneca Cardiovascular Disease Drugs Product Portfolio Table 120. AstraZeneca Recent Development Table 121. United Therapeutics Corporation Company Information Table 122. United Therapeutics Corporation Business Overview Table 123. United Therapeutics Corporation Cardiovascular Disease Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. United Therapeutics Corporation Cardiovascular Disease Drugs Product Portfolio Table 125. United Therapeutics Corporation Recent Development Table 126. Daiichi Sankyo Company Limited Company Information Table 127. Daiichi Sankyo Company Limited Business Overview Table 128. Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Product Portfolio Table 130. Daiichi Sankyo Company Limited Recent Development Table 131. Boehringer Ingelheim Company Information Table 132. Boehringer Ingelheim Business Overview Table 133. Boehringer Ingelheim Cardiovascular Disease Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Boehringer Ingelheim Cardiovascular Disease Drugs Product Portfolio Table 135. Boehringer Ingelheim Recent Development Table 136. Astellas Pharma Company Information Table 137. Astellas Pharma Business Overview Table 138. Astellas Pharma Cardiovascular Disease Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Astellas Pharma Cardiovascular Disease Drugs Product Portfolio Table 140. Astellas Pharma Recent Development Table 141. Actelion Pharmaceuticals Company Information Table 142. Actelion Pharmaceuticals Business Overview Table 143. Actelion Pharmaceuticals Cardiovascular Disease Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Actelion Pharmaceuticals Cardiovascular Disease Drugs Product Portfolio Table 145. Actelion Pharmaceuticals Recent Development Table 146. Key Raw Materials Table 147. Raw Materials Key Suppliers Table 148. Cardiovascular Disease Drugs Distributors List Table 149. Cardiovascular Disease Drugs Customers List Table 150. Research Programs/Design for This Report Table 151. Authors List of This Report Table 152. Secondary Sources Table 153. Primary Sources List of Figures Figure 1. Cardiovascular Disease Drugs Product Image Figure 2. Global Cardiovascular Disease Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cardiovascular Disease Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Cardiovascular Disease Drugs Sales (2021-2032) & (W Units) Figure 5. Global Cardiovascular Disease Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Cardiovascular Disease Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Lotrel Image Figure 10. Zebeta Image Figure 11. Coumadin Image Figure 12. Sectral Image Figure 13. Heparin Image Figure 14. Lopressor Image Figure 15. Norvasc Image Figure 16. Toprol XL Image Figure 17. Others Image Figure 18. Global Cardiovascular Disease Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 19. Global Cardiovascular Disease Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 20. Global Cardiovascular Disease Drugs Sales Volume Share by Type (2021-2032) Figure 21. Global Cardiovascular Disease Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Cardiovascular Disease Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 23. Global Cardiovascular Disease Drugs Sales Value Share by Type (2021-2032) Figure 24. Stroke Image Figure 25. Dyslipidemia Image Figure 26. Thrombosis Image Figure 27. Peripheral Artery Disease Image Figure 28. Asischemic Heart Disease Image Figure 29. Coronary Artery Diseases Image Figure 30. Atherosclerosis Image Figure 31. Others Image Figure 32. Global Cardiovascular Disease Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 33. Global Cardiovascular Disease Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 34. Global Cardiovascular Disease Drugs Sales Volume Share by Application (2021-2032) Figure 35. Global Cardiovascular Disease Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Cardiovascular Disease Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 37. Global Cardiovascular Disease Drugs Sales Value Share by Application (2021-2032) Figure 38. Global Cardiovascular Disease Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 39. Global Cardiovascular Disease Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 40. Global Cardiovascular Disease Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 41. Global Cardiovascular Disease Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 42. North America Cardiovascular Disease Drugs Sales Value (2021-2032) & (US$ Million) Figure 43. North America Cardiovascular Disease Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 44. Europe Cardiovascular Disease Drugs Sales Value (2021-2032) & (US$ Million) Figure 45. Europe Cardiovascular Disease Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 46. Asia-Pacific Cardiovascular Disease Drugs Sales Value (2021-2032) & (US$ Million) Figure 47. Asia-Pacific Cardiovascular Disease Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 48. South America Cardiovascular Disease Drugs Sales Value (2021-2032) & (US$ Million) Figure 49. South America Cardiovascular Disease Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 50. Middle East & Africa Cardiovascular Disease Drugs Sales Value (2021-2032) & (US$ Million) Figure 51. Middle East & Africa Cardiovascular Disease Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 52. USA Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. USA Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. USA Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Canada Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Canada Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Canada Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Mexico Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Mexico Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Mexico Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Germany Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Germany Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Germany Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. France Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. France Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. France Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. U.K. Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. U.K. Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. U.K. Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Italy Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Italy Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Italy Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Spain Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Spain Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Spain Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Russia Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Russia Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Russia Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Netherlands Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Netherlands Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Netherlands Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Nordic Countries Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Nordic Countries Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Nordic Countries Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. China Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. China Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. China Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Japan Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Japan Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Japan Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. South Korea Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. South Korea Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. South Korea Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. India Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. India Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. India Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Australia Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Australia Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Australia Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Southeast Asia Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Southeast Asia Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Southeast Asia Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Brazil Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Brazil Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Brazil Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Argentina Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Argentina Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Argentina Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Chile Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Chile Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Chile Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Colombia Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Colombia Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Colombia Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Peru Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Peru Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Peru Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Saudi Arabia Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Saudi Arabia Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Saudi Arabia Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Israel Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Israel Arabia Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Israel Arabia Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. UAE Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. UAE Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. UAE Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Turkey Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 128. Turkey Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 129. Turkey Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 130. Iran Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 131. Iran Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 132. Iran Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 133. Egypt Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 134. Egypt Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 135. Egypt Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 136. Cardiovascular Disease Drugs Value Chain Figure 137. Manufacturing Cost Structure Figure 138. Cardiovascular Disease Drugs Sales Mode & Process Figure 139. Direct Comparison with Distribution Share Figure 140. Distributors Profiles Figure 141. Years Considered Figure 142. Research Process Figure 143. Key Executives Interviewed

Scope & coverage.

Types
  • Lotrel
  • Zebeta
  • Coumadin
  • Sectral
  • Heparin
  • Lopressor
  • Norvasc
  • Toprol XL
  • Others
Applications
  • Stroke
  • Dyslipidemia
  • Thrombosis
  • Peripheral Artery Disease
  • Asischemic Heart Disease
  • Coronary Artery Diseases
  • Atherosclerosis
  • Others
Companies covered
  • Takeda Pharmaceutical
  • Sanofi
  • Johnson＆Johnson
  • Novartis
  • Merck
  • Roche
  • Pfizer
  • Bayer
  • AstraZeneca
  • United Therapeutics Corporation
  • Daiichi Sankyo Company Limited
  • Boehringer Ingelheim
  • Astellas Pharma
  • Actelion Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Cardiovascular Disease Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Cardiovascular Disease Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Cardiovascular Disease Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Cardiovascular Disease Drugs Market Dynamics
  1. 2.1 Cardiovascular Disease Drugs Industry Trends
  2. 2.2 Cardiovascular Disease Drugs Industry Drivers
  3. 2.3 Cardiovascular Disease Drugs Industry Opportunities and Challenges
  4. 2.4 Cardiovascular Disease Drugs Industry Restraints
3 Cardiovascular Disease Drugs Market by Company
  1. 3.1 Global Cardiovascular Disease Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Cardiovascular Disease Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Cardiovascular Disease Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Cardiovascular Disease Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Cardiovascular Disease Drugs Company Ranking (2024-2026)
  6. 3.6 Global Cardiovascular Disease Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Cardiovascular Disease Drugs Company Product Type and Application
  8. 3.8 Global Cardiovascular Disease Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Cardiovascular Disease Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Cardiovascular Disease Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Cardiovascular Disease Drugs Market by Type
  1. 4.1 Cardiovascular Disease Drugs Type Introduction
  2. 4.1.1 Lotrel
  3. 4.1.2 Zebeta
  4. 4.1.3 Coumadin
  5. 4.1.4 Sectral
  6. 4.1.5 Heparin
  7. 4.1.6 Lopressor
  8. 4.1.7 Norvasc
  9. 4.1.8 Toprol XL
  10. 4.1.9 Others
  11. 4.2 Global Cardiovascular Disease Drugs Sales Volume by Type
  12. 4.2.1 Global Cardiovascular Disease Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  13. 4.2.2 Global Cardiovascular Disease Drugs Sales Volume by Type (2021-2032)
  14. 4.2.3 Global Cardiovascular Disease Drugs Sales Volume Share by Type (2021-2032)
  15. 4.3 Global Cardiovascular Disease Drugs Sales Value by Type
  16. 4.3.1 Global Cardiovascular Disease Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  17. 4.3.2 Global Cardiovascular Disease Drugs Sales Value by Type (2021-2032)
  18. 4.3.3 Global Cardiovascular Disease Drugs Sales Value Share by Type (2021-2032)
5 Cardiovascular Disease Drugs Market by Application
  1. 5.1 Cardiovascular Disease Drugs Application Introduction
  2. 5.1.1 Stroke
  3. 5.1.2 Dyslipidemia
  4. 5.1.3 Thrombosis
  5. 5.1.4 Peripheral Artery Disease
  6. 5.1.5 Asischemic Heart Disease
  7. 5.1.6 Coronary Artery Diseases
  8. 5.1.7 Atherosclerosis
  9. 5.1.8 Others
  10. 5.2 Global Cardiovascular Disease Drugs Sales Volume by Application
  11. 5.2.1 Global Cardiovascular Disease Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  12. 5.2.2 Global Cardiovascular Disease Drugs Sales Volume by Application (2021-2032)
  13. 5.2.3 Global Cardiovascular Disease Drugs Sales Volume Share by Application (2021-2032)
  14. 5.3 Global Cardiovascular Disease Drugs Sales Value by Application
  15. 5.3.1 Global Cardiovascular Disease Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  16. 5.3.2 Global Cardiovascular Disease Drugs Sales Value by Application (2021-2032)
  17. 5.3.3 Global Cardiovascular Disease Drugs Sales Value Share by Application (2021-2032)
6 Cardiovascular Disease Drugs Regional Sales and Value Analysis
  1. 6.1 Global Cardiovascular Disease Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cardiovascular Disease Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Cardiovascular Disease Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Cardiovascular Disease Drugs Sales by Region (2027-2032)
  5. 6.3 Global Cardiovascular Disease Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Cardiovascular Disease Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Cardiovascular Disease Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Cardiovascular Disease Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Cardiovascular Disease Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Cardiovascular Disease Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Cardiovascular Disease Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Cardiovascular Disease Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Cardiovascular Disease Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Cardiovascular Disease Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Cardiovascular Disease Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Cardiovascular Disease Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Cardiovascular Disease Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Cardiovascular Disease Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Cardiovascular Disease Drugs Sales Value Share by Country, 2025 VS 2032
7 Cardiovascular Disease Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Cardiovascular Disease Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Cardiovascular Disease Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Cardiovascular Disease Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Cardiovascular Disease Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Cardiovascular Disease Drugs Sales by Country (2027-2032)
  6. 7.4 Global Cardiovascular Disease Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Cardiovascular Disease Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Cardiovascular Disease Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Cardiovascular Disease Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Cardiovascular Disease Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Cardiovascular Disease Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceutical
  2. 8.1.1 Takeda Pharmaceutical Company Information
  3. 8.1.2 Takeda Pharmaceutical Business Overview
  4. 8.1.3 Takeda Pharmaceutical Cardiovascular Disease Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceutical Cardiovascular Disease Drugs Product Portfolio
  6. 8.1.5 Takeda Pharmaceutical Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Cardiovascular Disease Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Cardiovascular Disease Drugs Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Johnson＆Johnson
  14. 8.3.1 Johnson＆Johnson Company Information
  15. 8.3.2 Johnson＆Johnson Business Overview
  16. 8.3.3 Johnson＆Johnson Cardiovascular Disease Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Johnson＆Johnson Cardiovascular Disease Drugs Product Portfolio
  18. 8.3.5 Johnson＆Johnson Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Cardiovascular Disease Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Cardiovascular Disease Drugs Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Merck
  26. 8.5.1 Merck Company Information
  27. 8.5.2 Merck Business Overview
  28. 8.5.3 Merck Cardiovascular Disease Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Merck Cardiovascular Disease Drugs Product Portfolio
  30. 8.5.5 Merck Recent Developments
  31. 8.6 Roche
  32. 8.6.1 Roche Company Information
  33. 8.6.2 Roche Business Overview
  34. 8.6.3 Roche Cardiovascular Disease Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Roche Cardiovascular Disease Drugs Product Portfolio
  36. 8.6.5 Roche Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Cardiovascular Disease Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Cardiovascular Disease Drugs Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Bayer
  44. 8.8.1 Bayer Company Information
  45. 8.8.2 Bayer Business Overview
  46. 8.8.3 Bayer Cardiovascular Disease Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Bayer Cardiovascular Disease Drugs Product Portfolio
  48. 8.8.5 Bayer Recent Developments
  49. 8.9 AstraZeneca
  50. 8.9.1 AstraZeneca Company Information
  51. 8.9.2 AstraZeneca Business Overview
  52. 8.9.3 AstraZeneca Cardiovascular Disease Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 AstraZeneca Cardiovascular Disease Drugs Product Portfolio
  54. 8.9.5 AstraZeneca Recent Developments
  55. 8.10 United Therapeutics Corporation
  56. 8.10.1 United Therapeutics Corporation Company Information
  57. 8.10.2 United Therapeutics Corporation Business Overview
  58. 8.10.3 United Therapeutics Corporation Cardiovascular Disease Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 United Therapeutics Corporation Cardiovascular Disease Drugs Product Portfolio
  60. 8.10.5 United Therapeutics Corporation Recent Developments
  61. 8.11 Daiichi Sankyo Company Limited
  62. 8.11.1 Daiichi Sankyo Company Limited Company Information
  63. 8.11.2 Daiichi Sankyo Company Limited Business Overview
  64. 8.11.3 Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Product Portfolio
  66. 8.11.5 Daiichi Sankyo Company Limited Recent Developments
  67. 8.12 Boehringer Ingelheim
  68. 8.12.1 Boehringer Ingelheim Company Information
  69. 8.12.2 Boehringer Ingelheim Business Overview
  70. 8.12.3 Boehringer Ingelheim Cardiovascular Disease Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Boehringer Ingelheim Cardiovascular Disease Drugs Product Portfolio
  72. 8.12.5 Boehringer Ingelheim Recent Developments
  73. 8.13 Astellas Pharma
  74. 8.13.1 Astellas Pharma Company Information
  75. 8.13.2 Astellas Pharma Business Overview
  76. 8.13.3 Astellas Pharma Cardiovascular Disease Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Astellas Pharma Cardiovascular Disease Drugs Product Portfolio
  78. 8.13.5 Astellas Pharma Recent Developments
  79. 8.14 Actelion Pharmaceuticals
  80. 8.14.1 Actelion Pharmaceuticals Company Information
  81. 8.14.2 Actelion Pharmaceuticals Business Overview
  82. 8.14.3 Actelion Pharmaceuticals Cardiovascular Disease Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Actelion Pharmaceuticals Cardiovascular Disease Drugs Product Portfolio
  84. 8.14.5 Actelion Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Cardiovascular Disease Drugs Value Chain Analysis
  2. 9.1.1 Cardiovascular Disease Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Cardiovascular Disease Drugs Sales Mode & Process
  6. 9.2 Cardiovascular Disease Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Cardiovascular Disease Drugs Distributors
  9. 9.2.3 Cardiovascular Disease Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst